# Sex-based differences in clearance of chronic Plasmodium

falciparum infection

- 4 Jessica Briggs, M.D.<sup>1\*</sup>, Noam Teyssier, B.S.<sup>1</sup>, Joaniter I. Nankabirwa, Ph.D.<sup>2,3</sup>, John Rek, MSc<sup>2</sup>,
- 5 Prasanna Jagannathan, M.D.<sup>4</sup>, Emmanuel Arinatiwe, MPH<sup>2,9</sup>, Teun Bousema, Ph.D.<sup>5, 6</sup>, Chris
- 6 Drakeley, Ph.D.<sup>6</sup>, Margaret Murray, M.S.<sup>4</sup>, Emily Crawford, Ph.D.<sup>7</sup>, Nicholas Hathaway, M.D.<sup>8</sup>,
- 7 Sarah G. Staedke, Ph.D.<sup>9</sup>, David Smith, Ph.D.<sup>10</sup>, Phillip J. Rosenthal, M.D.<sup>1</sup>, Moses Kamya,
- 8 Ph.D.<sup>2,3</sup>, Grant Dorsey, M.D.<sup>1</sup>, Isabel Rodriguez-Barraquer, M.D.<sup>1</sup>\*\*,
- 9 Bryan Greenhouse, M.D.<sup>1</sup> \*\*
- 10 \*\*co-senior authors

1

2

11

24252627

31

32

33

- 12 Department of Medicine, University of California San Francisco, San Francisco, CA
- 13 <sup>2</sup>Infectious Diseases Research Collaboration, Kampala, Uganda
- 14 Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda
- 15 <sup>4</sup> Department of Medicine, Stanford University, Palo Alto, CA
- <sup>5</sup> Department of Medical Microbiology, Radboud University Nijmegen Medical Centre,
- 17 Nijmegen, the Netherlands
- 18 <sup>6</sup> Department of Immunology and Infection, London School of Hygiene and Tropical Medicine,
- 19 London, UK
- 20 <sup>7</sup> Chan-Zuckerberg Biohub, San Francisco, CA
- <sup>8</sup> Department of Medicine, University of Massachusetts, Amherst, MA
- <sup>9</sup> Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK
- 23 <sup>10</sup>Institute for Health Metrics & Evaluation, University of Washington, Seattle, WA

- 28 \*Corresponding Author: Jessica Briggs, Rm 525 Building 3, Zuckerberg San Francisco
- 29 General Hospital, San Francisco, CA. Email: <a href="mailto:jessica.briggs@ucsf.edu">jessica.briggs@ucsf.edu</a>
  30

- **Key words:** malaria, asymptomatic infection, force of infection, duration of infection,
- 39 genotyping, sex-based differences

Abstract Multiple studies have reported a male bias in incidence and/or prevalence of malaria infection in males compared to females. To test the hypothesis that sex-based differences in host-parasite interactions affect the epidemiology of malaria, we intensively followed *Plasmodium falciparum* infections in a cohort in a malaria endemic area of eastern Uganda and estimated both force of infection (FOI) and rate of clearance using amplicon deep-sequencing. We found no evidence of differences in behavioral risk factors, incidence of malaria, or FOI by sex. In contrast, females cleared asymptomatic infections at a faster rate than males (hazard ratio [HR] = 1.82, 95% CI 1.20 to 2.75 by clone and HR = 2.07, 95% CI 1.24 to 3.47 by infection event) in multivariate models adjusted for age, timing of infection onset, and parasite density. These findings implicate biological sex-based differences as an important factor in the host response to this globally important pathogen.

# Introduction

Malaria, a protozoan infection of the red blood cells, remains one of the greatest global health challenges<sup>1</sup>. Infection with malaria parasites results in a wide range of clinical disease presentations, from severe to uncomplicated; in addition, in hyperendemic areas, asymptomatic infections are common<sup>2</sup>. It is well established that chronic asymptomatic infection with *Plasmodium falciparum*, the most common and fatal malaria parasite, can lead to morbidity for those infected and contribute to ongoing transmission<sup>2–5</sup>. Characterization of these asymptomatic infections is paramount as they represent a major obstacle for malaria elimination efforts. Therefore, an understanding of how host immunity and parasite factors interact to cause disease tolerance is required. While age-specific immunity to malaria in hyperendemic areas is well-characterized, less attention has been paid to the possibility of a sex bias in malarial susceptibility despite evidence for a male bias in malaria infections in non-human animals and a male bias in the prevalence of other human parasitic infections<sup>6–8</sup>.

The clearest evidence for sexual dimorphism in malaria susceptibility is in pregnant women, who are at greater risk of malaria infection and also experience more severe disease and higher mortality<sup>9</sup>. However, multiple studies performed in different contexts have demonstrated a male bias in incidence and/or prevalence of malaria infection in school aged children and adults; <sup>10–14</sup> this bias is more well established in hypoendemic areas, but has also been observed in hyperendemic regions. <sup>15,16</sup> It has often been postulated that these differences in malaria incidence or prevalence stem from an increased risk of males acquiring infection due to socio-behavioral factors <sup>11,13,17,18</sup>. However, biological sex itself has been demonstrated to affect responses to other pathogens, and thus an alternative hypothesis is that the sexes have different responses to the malaria parasite once infected <sup>19–22</sup>.

Estimating the host response to *P. falciparum* infection requires close follow up of infected individuals, sensitive detection of parasites, and the ability to distinguish superinfection, which is common in endemic areas, from persistent infection. To test the hypothesis that sexbased differences in host-parasite interactions affect the epidemiology of malaria, we intensively followed a representative cohort of individuals living in a malaria endemic area of eastern Uganda. Using frequent sampling, ultrasensitive quantitative PCR (qPCR), and amplicon deep sequencing to genotype parasite clones, we were able to accurately detect the onset of new infections and follow all infections over time to estimate their duration. Using these data, we show that females cleared their asymptomatic infections more rapidly than males, implicating biological sex-based differences as important in the host response to this globally important pathogen.

## **Results**

#### Cohort participants and *P. falciparum* infections

This analysis involved data from 477 children and adults (233 males and 244 females) that were followed for a total of 669.6 person-years (Table 1). 25 participants, 10 males and 15 females, were enrolled after initial enrollment (Figure 1); median duration of follow up in those who were dynamically enrolled was 0.84 years (IQR 0.69-1.23) compared to 1.45 years (IQR 1.43-1.47) in those enrolled during initial enrollment. 149 of 477 participants (31.2%) included in the analysis had at least one *P. falciparum* infection detected (Figure 1). 114 participants had 822 successfully genotyped samples and had infections characterized by clone and by infection event. We achieved a read count of >10,000 for 92% of genotyped samples, identifying 45 unique AMA-1 clones in our population (frequencies and sequences in **Supplemental File 1e**). 35 samples had very low-density infections (< 1 parasite/µL) that could not be genotyped and had infections characterized at the event level only. There were more baseline infections in

males at the clone level, with 117/185 (63.2%) baseline infections in males and 68/185 (36.8%) baseline infections in females (p <0.001). At the infection event level, there was no difference in the number of baseline infections by sex, with 54/99 (54.4%) baseline infections in males and 45/99 (45.5%) baseline infections in females and (p = 0.26).

#### Behavioral malaria risk factors and measures of malaria burden

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

There was no difference in reported rates of LLIN use the previous night by sex (Table 1). Women over the age of 16 traveled overnight outside of the study area more than men (incidence rate ratio [IRR] for females vs. males = 3.61, 95% confidence interval [CI] 1.83 to 7.13), a potential risk factor for malaria exposure. Antimalarial use outside the study clinic was reported only 4 times (3 females and 1 male, all under the age of 5). In this region receiving regular rounds of IRS, the incidence of symptomatic malaria was low in all age categories, and there was no evidence of a difference in incidence of symptomatic malaria by sex overall (IRR for females vs. males = 1.11, 95% CI 0.49 to 2.52) or when adjusted for age (IRR = 1.26, 95% CI 0.54 to 2.96). In contrast, prevalence ratio (PR) of *P. falciparum* parasitemia by microscopy in females versus males across all age categories was 0.49 (95% CI 0.36 to 0.65), with relative differences in prevalence most pronounced in the oldest age group. Similar findings were seen when prevalence was assessed by ultrasensitive qPCR, with PR = 0.64 in females vs. males (95% CI 0.43 to 0.96), again with the largest differences seen in the oldest age group. Adjusting for age as a categorical variable, LLIN use, and travel did not qualitatively change prevalence ratios for microscopic parasitemia (PR in females vs. males = 0.57, 95% CI 0.42 to 0.77) or for qPCR-positive parasitemia (PR in females vs. males = 0.67, 95% CI 0.60 to 0.76). We also found no evidence for a difference in parasite density as determined by qPCR between males and females after adjusting for age as a continuous variable (p = 0.47). Median COI was higher in males than in females overall, driven primarily by a higher COI in male school aged children.

### Force of infection by age and sex

To determine whether higher infection prevalence in males was due to an increased rate of infection, we used longitudinal genotyping to calculate the force of infection (FOI, number of new blood stage infections per unit time). Overall, the FOI was low, with new infections occurring on average less than once every 5 years (Table 2). There was no evidence for a significant difference in FOI by sex overall (IRR for females vs. males = 0.88, 95% CI 0.48 to 1.62 by clone and IRR = 0.83, 95% CI 0.52 to 1.33 by infection event). There was also no evidence for a significant difference in FOI by sex when adjusted for age category (IRR = 0.88, 95% CI 0.47 to 1.63 by clone and IRR = 0.83, 95% CI 0.53 to 1.31 by infection event). For analysis both by clone and by infection event, there was a trend toward higher FOI in males compared to females. We performed a sensitivity analysis by decreasing the number of skips necessary to declare an infection cleared (Supplemental File 1f). Performing the same analysis using 1 skip for clearance instead of 3 skips increased the FOI in all groups and increased the trend toward higher FOI in males, with IRR for females vs. males when adjusted for age category = 0.71, 95% CI 0.41 to 1.24 by clone and IRR = 0.75, 95% CI 0.47 to 1.22 by infection event.

#### Rate of clearance of infection and duration of infection by sex

Since females had a lower prevalence of infection but similar rate of acquiring infections compared to males, we evaluated whether there was a difference between sexes in the rate at which infections were cleared. Asymptomatic infections were included in this analysis if they were not censored as stated in the methods; at the clone level, 105 baseline infections and 53 new infections were included. At the infection event level, 58 baseline infections and 51 new infections were included. There were more baseline infections in males at the clone level, with 68/105 (64.8%) baseline infections in males and 37/105 (35.2%) baseline infections in females (p <0.001). At the infection event level, there was no difference in the number of baseline

infections by sex, with 32/58 (55.2%) baseline infections in males and 26/58 (44.8%) baseline infections in females (p = 0.35).

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

Unadjusted hazard ratios for clearing infecting clones showed that asymptomatic infections cleared naturally (i.e., when not treated by antimalarials) at nearly twice the rate in females vs. males (hazard ratio (HR) 1.92, 95% CI 1.19 to 3.11, Table 3). In addition, new infections cleared faster than baseline infections and monoclonal infections cleared faster than polyclonal infections. Unadjusted hazard ratios for clearance of infection events (as opposed to clones) also showed faster clearance in females vs. males (HR = 2.30, 95% CI 1.20 to 4.42). Results were similar in multivariate models including age, gender, the period during which the infection was first observed, and parasite density, demonstrating faster clearance in females vs. males (HR =1.82, 95% CI 1.20 to 2.75 by clone and HR =2.07, 95% CI 1.24 to 3.47 by infection event). Complexity of infection was not included in the final adjusted model because the model fit the data less well when COI was included as a predictor. In both adjusted models, new infections cleared faster than baseline infections. Higher parasite densities were associated with slower clearance by clone and by infection event, but the effect size was larger when data were analyzed by infection event (HR = 0.44, 95% CI 0.35 to 0.54). There was no evidence for interaction between age and sex in either adjusted model. We performed a sensitivity analysis by decreasing the number of skips necessary to declare an infection cleared. Regardless of whether 3 skips, 2 skips, or 1 skip was used to determine infection clearance, females cleared their infections faster than males both by clone and by infection event (Supplemental File 1g).

We next estimated durations of asymptomatic infection by age and sex using results from a model that included these covariates (Figure 2). Durations of infection ranged from 103 days to 447 days by clone, and from 87 to 536 days by infection event. Males had a longer duration of infection across all age categories. Children aged 5-15 years had the longest duration of infection, followed by adults. Therefore, overall, males aged 5-15 years had the longest estimated duration of infection by either clone (447 days) or infection event (526 days).

### Discussion

Previous studies have reported a higher prevalence of malaria infection in males compared to females, with the difference often ascribed to differences in exposure<sup>10–16</sup>. In a cohort study in eastern Uganda, we noted higher prevalence of malaria infection in males compared to females. By closely following a cohort of children and adults and genotyping every detected infection with sensitive amplicon deep-sequencing, we were able to estimate both the rate of infection (FOI) and duration of infection and to compare these measures by sex. We found that lower prevalence in females did not appear to be due to lower rates of infection but rather due to faster clearance of asymptomatic infections. To our knowledge, this is the first study to report a sex-based difference in the duration of malaria infection.

Many prior studies of malaria incidence and/or prevalence that evaluated associations with sex in late childhood, adolescence and adulthood have found a male bias in the observed measure of burden<sup>10–16</sup>. Overall, these studies consistently suggest that males exhibit higher incidence and/or prevalence of malaria that begins during late childhood, persisting through puberty and the majority of adulthood (excepting the years when pregnancy puts women at higher risk). One possible explanation put forward for the sex-specific difference in burden has been that males are more frequently bitten by malaria-carrying mosquitos due to behavioral differences such as working outside, not sleeping under a net, or traveling for work<sup>11,13,17,18</sup>. In our study, however, there were no statistically significant differences in malaria incidence or FOI by sex, though there was a trend toward higher FOI in males. We also saw no evidence of behavioral trends that would result in more infections in males; in fact, older women in our study did most of the traveling outside the study area (an area of low transmission compared to surrounding areas). We did not assess work habits as part of our study questionnaire, but the fact that we observe similar patterns in prevalence by sex in all age categories makes this a less

likely explanation. Therefore, in this particular cohort, it appears that the observed male bias in parasite prevalence is best explained by slower clearance of infection in males. We cannot rule out that males were differentially exposed in the recent past (e.g., had a higher force of infection when transmission was higher, which could have affected immunity), and we plan to genotype samples from a prior cohort from 2011-2017 to test this hypothesis.

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

Very few studies have been conducted to explore immunological differences between males and females in their response to the malaria parasite. RTS,S vaccination is associated with higher all-cause mortality in girls compared to boys, and a trend toward higher risk of fatal malaria has been noted in vaccinated girls compared to boys, suggesting possible sexual dimorphism in immunological responses to malaria<sup>23</sup>. The comprehensive Garki project found that females had higher levels of antibodies against *P. falciparum* compared to men<sup>10</sup>. Hormonal differences have been posited to play a role in these sex-based immunological differences to malaria infection; studies in mice show that testosterone appears to downregulate the immune response to malaria<sup>24,25</sup>. If sex-based differences were purely hormonally mediated, one might expect a stronger effect in adults than in school-aged children, which was not seen in this cohort. This could be due to imperfect detectability, as adults have lower density infections than school-aged children due to improved anti-parasite immunity<sup>2,3</sup>. Post-menopausal women were also included in the oldest age group, which could have blunted the effect of sex in that age group if there is a hormonal basis for some of this effect. It is also possible that sex-based differences are explained by a different mechanism, such as differences in innate immunity. More studies are needed to elucidate the relationship between sex-based biological differences between males and females and their impact on the development of effective antimalarial immunity in humans.

Of the variables we evaluated in addition to sex, baseline infection status and parasite density were most strongly associated with the rate of clearance of infection. Infections that were already present at the beginning of the study and persisted past the left censoring date

may have been a non-random selection of well-established asymptomatic infections that were present at baseline at a higher frequency than average because they had a fundamentally different trajectory than newly established asymptomatic infections. Higher parasite densities were also associated with slower clearance of infection in both adjusted models, but the effect was most pronounced when the data were analyzed by infection event. This may be because low-density infections that we were unable to successfully genotype were only included in the infection event analysis, and these events tended to have short durations. The inclusion of parasite density in our multivariate models did not meaningfully alter associations between sex and duration of infection, providing evidence that the sex-based differences in duration were not mediated primarily by differences in parasite density in our cohort.

A limitation of our study is the statistical model's assumption that all infections clear at the same rate, which was necessary because we did not observe the beginning of most infections. To rely less on this assumption, we adjusted for baseline infections, allowing them to have a different rate of clearance than new infections; this did not change our primary finding of a difference in rate of clearance by sex. We also acknowledge there may be other unmeasured confounders, such as genetic hemoglobinopathies or sex-based differences in unreported outside antimalarial use, that could affect our results. Another caveat is that our findings may not be generalizable to areas with different transmission intensity given that our study was conducted in a unique area with previously very high transmission intensity that has been greatly reduced in recent years by repeated rounds of IRS.

Additionally, because it is difficult to genotype low density infections and because parasite densities fluctuate over time, we allowed several "skips" in detection before declaring an infection cleared or the same clone in an individual a new infection with the same clone. This requires the assumption that re-infection with the same clone is relatively rare, which is reasonable given the high genetic diversity and low force of infection seen in this setting; this

assumption has been made in other longitudinal genotyping studies<sup>26,27</sup>. Our method may have biased us toward longer durations of infection and fewer new infections overall, but this is unlikely to have introduced any significant bias in the observed associations by sex. We performed a sensitivity analysis to ensure that changing the number of skips allowed did not significantly change the main finding regarding longer duration of infection in males and our findings were consistent. Given decreasing parasite densities over time and a setting with low force of infection and low EIR, assuming perfect recovery of clones is likely to artificially inflate the force of infection in this cohort.

In summary, we estimated the clearance of asymptomatic *P. falciparum* infections by genotyping longitudinal samples from a cohort in Nagongera, Uganda, using sensitive amplicon deep-sequencing and found that females cleared their infections at a faster rate than males; this finding remained consistent when adjusting for age, baseline infection status, and parasite density. Furthermore, we found no conclusive evidence for a sex-based difference in exposure to infection, either behaviorally or by FOI. Though there have long been observed differences in malaria burden between the sexes, there is still little known about sex-based biological differences that may mediate immunity to malaria. Unfortunately, much reported malaria data is still sex-disaggregated. Our findings should encourage epidemiologists to better characterize sexual dimorphism in malaria and motivate increased research into biological explanations for sex-based differences in the host response to the malaria parasite.

## **Materials and Methods**

#### Study setting and population-level malaria control interventions

This cohort study was carried out in Nagongera sub-county, Tororo district, eastern Uganda, an area with historically high malaria transmission. However, 7 rounds of indoor residual spraying (IRS) from 2014-2019 have resulted in a significant decline in the burden of

malaria<sup>28</sup>. Pre-IRS, the daily human biting rate (HBR) was 34.3 and the annual entomological inoculation rate (EIR) was 238; after 5 years of IRS, in 2019 the daily HBR was 2.07 and overall annual EIR was 0.43 as reported by Nankabirwa et. al.<sup>29</sup>

### Study design, enrollment, and follow-up

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

All members of 80 randomly selected households with at least two children were enrolled in October 2017 using a list generated by enumerating and mapping all households in Nagongera sub-county<sup>29</sup>. The cohort was dynamic such that residents joining the household were enrolled and residents leaving the household were withdrawn. Data for this analysis was collected from October 1<sup>st</sup>, 2017 through March 31<sup>st</sup>, 2019; participants were included if they had at least 6 months of contiguous follow up. Participants were followed at a designated study clinic open daily from 8 AM to 5 PM. Participants were encouraged to seek all medical care at the study clinic and avoid the use of antimalarial medications outside of the study. Routine visits were conducted every 28 days and included a standardized clinical evaluation, assessment of overnight travel outside of Nagongera sub-county, and collection of blood by phlebotomy for detection of malaria parasites by microscopy and molecular studies. Participants came in for non-routine visits in the setting of illness. Blood smears were performed at enrollment, at all routine visits and at non-routine visits if the participant presented with fever or history of fever in the previous 24 hours. Participants with fever (>38.0°C tympanic) or history of fever in the previous 24 hours had a thick blood smear read urgently. If the smear was positive, the patient was diagnosed with malaria and treated with artemether-lumefantrine. Participants with asymptomatic parasitemia as detected by qPCR or microscopy were not treated with antimalarials, consistent with Uganda national guidelines. Study participants were visited at home every 2 weeks to assess use of long-lasting insecticidal nets (LLINs) the previous night.

### **Laboratory methods**

Thick blood smears were stained with 2% Giemsa for 30 minutes and evaluated for the presence of asexual parasites and gametocytes. Parasite densities were calculated by counting the number of asexual parasites per 200 leukocytes (or per 500, if the count was less than 10 parasites per 200 leukocytes), assuming a leukocyte count of 8,000/µl. A thick blood smear was considered negative if examination of 100 high power fields revealed no asexual parasites. For quality control, all slides were read by a second microscopist, and a third reviewer settled any discrepant readings. In our experienced microscopists' hands, the lower limit of detection is approximately 20-50 parasites/µL.

For qPCR and genotyping, we collected 200  $\mu$ L of blood at enrollment, at each routine visit, and at the time of malaria diagnosis. DNA was extracted using the PureLink Genomic DNA Mini Kit (Invitrogen) and parasitemia was quantified using an ultrasensitive varATS qPCR assay with a lower limit of detection of 0.05 parasites/ $\mu$ L<sup>30</sup>. Samples with a parasite density >= 0.1 parasites/ $\mu$ L blood were genotyped via amplicon deep-sequencing. All samples positive for asexual parasites by microscopy but negative for *P. falciparum* by qPCR were tested for the presence of non-falciparum species using nested PCR.<sup>31</sup>

#### Sequencing library preparation

Hemi-nested PCR was used to amplify a 236 base-pair segment of apical membrane antigen 1 (AMA-1) using a published protocol<sup>32</sup>, with modifications (**Supplemental File 1a**). Samples were amplified in duplicate, indexed, pooled, and purified by bead cleaning. Sequencing was performed on an Illumina MiSeq platform (250bp paired-end).

#### **Bioinformatics methods**

Data extraction, processing, and haplotype clustering were performed using SeekDeep<sup>33</sup>, followed by additional filtering<sup>34</sup>. **Supplemental File 1b** shows the full bioinformatics workflow.

### Data analysis

A clone was defined as a genetically identical group of parasites, e.g., with identical haplotypes. Because polyclonal infections can occur due to co-infection (one mosquito bite transmitting multiple clones) or superinfection (multiple bites), we analyzed the infection data both by clone and by infection event. For analysis by clone, each unique clone was counted as an infection and each clone's disappearance as a clearance event. For analysis by infection event, any new clones seen within 3 visits of the date of the first newly detected clone(s) were grouped together and considered one new "infection event." Clearance of infection for these events required that all clones in the group be absent. A baseline infection was defined as a clone or infection event (group of clones) detected in the first 60 days of observation. New infections were defined as a new clone or infection event (group of clones) detected in an individual after day 60.

Imperfect detection of *P. falciparum* clones is known to be a limitation of all PCR-based genotyping methods; both biological factors, such as deep organ sequestration of clones in the lifecycle of the parasite, and methodological factors, such as difficulty amplifying minority clones (especially at lower parasite densities), results in imperfect detectability of all clones present in a single blood sample drawn on a single day. <sup>26,35–38</sup> Though amplicon deep sequencing is less likely than other methods to miss minority clones <sup>39</sup>, detectability was a particular concern in our study, in which the majority of infections were submicroscopic and parasite densities declined over time [Supplemental File 1c]. To account for the fact that a clone might be missed in a single sample due to fluctuations in parasite density and/or methodological limitations, we allowed 3 "skips" in detection and classified an infection as cleared only if it was not identified in 4 contiguous samples from routine visits. If the infection (as determined by clone or by infection event) was absent for 4 routine samples in a row, the last date of detection would be the end date of that infection. Therefore, for a clone that had previously infected an individual to be

classified as a new infection, it had to have been absent from that individual for at least 4 routine visits. Additional details are found in **Supplemental File 1d**. This decision was supported by the fact that the diversity of the genotyped AMA-1 amplicon was quite high (expected heterozygosity = 0.949), resulting in a low probability (5.1%) for infection with the same clone by chance.

Data analysis was conducted in R<sup>40</sup> and Python<sup>41</sup>. Microscopic parasite prevalence was defined by the number of smear-positive routine visits over all routine visits. Parasite prevalence by qPCR was defined as the number of qPCR-positive visits over all routine visits. Prevalence ratios were computed using Poisson regression with generalized estimating equations to adjust for repeated measures. Comparison of parasite density by sex was made using linear regression with generalized estimating equations to adjust for repeated measures. Force of infection (FOI) was defined as the number of new infections, including malaria episodes, divided by person time. Poisson regression with generalized estimating equations to account for repeated measures was used to estimate malaria incidence, FOI, and to calculate incident rate ratios (IRR) for malaria and FOI. Hazards for clearance of untreated, asymptomatic infections were estimated using time-to-event models (shared frailty models fit using R package "frailtypack," version 2.12.2)<sup>42,43</sup>. Infections were censored if they were only observed in the first three months or the last three months (before January 01, 2018 and after January 01, 2019) because they were not observed for long enough to determine whether clearance occurred. If an infection was observed for only one timepoint, it was assigned a duration of 14 days. These models assumed a constant hazard of clearance and included random effects to account for repeated measures in individuals. Parasite density was included in the model as a time-varying covariate. Duration of infection in days was calculated as 1/adjusted hazard.

#### **Data Accessibility**

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385


386

387


Data from the cohort study is available through an open-access clinical epidemiology database resource, ClinEpiDB at https://clinepidb.org/ce/app/record/dataset/DS\_51b40fe2e2. Genotyping data and code used to generate tables and figures is available on GitHub<sup>44</sup>.

### Figure Legends

### Figure 1. Study design.



# Figure 2. Estimates of duration of infection from sex- and age-adjusted model



Estimated duration of infection in days, calculated by adjusting the point estimate of the baseline hazard by the coefficients of the sex- and age-adjusted model. Error bars represent standard errors of duration obtained from variance in the model coefficients. Point estimates of duration are labeled (\*).

**Supplemental File Legends** Supplemental File 1a. AMA-1 hemi-nested PCR protocol for amplicon deep-sequencing Supplemental File 1b: Bioinformatics workflow Supplemental File 1c. Declining qPCR density over time in the cohort. Supplemental File 1d. Detailed explanation of skip rule criteria Supplemental File 1e. Haplotype sequences and frequencies Supplemental File 1f. Sensitivity analysis of molecular force of infection: Table 2 replicated using 2 skips or 1 skip Supplemental File 1g. Sensitivity analysis of duration of infection: Table 3 replicated using 2 skips or 1 skip 

Table 1. Behavioral risk factors for malaria infection and measures of malaria burden in study population, stratified by age and sex 466 467

	Age and gender categories							
Metric	All		< 5 years old		5-15 years old		16 years and older	
	Male	Female	Male	Female	Male	Female	Male	Female
umber of participants, n	233	244	73	84	101	71	59	89
Nedian days of follow-up per participant	530.0	530.0	525.0	524.5	530.0	531.0	530.0	530.0
lept under LLIN the previous night	53.6%	56.3%	54.1%	56.3%	47.9%	47.8%	63.7%	64.3%
erson-years of follow up	324.2	345.4	87.3	96.7	152.6	118.5	84.22	130.1
Number of overnight trips	44	107	21	19	9	10	14	78
Incidence of overnight trips*, (95% CI)	0.14	0.31	0.24	0.20	0.06	0.08	0.17	0.60
	(0.09-0.20)	(0.20-0.49)	(0.14-0.42)	(0.09-0.42)	(0.03-0.13)	(0.03-0.24)	(0.09-0.31)	(0.30-1.1
Episodes of malaria**, (incidence*)	11	13	5	2	5	9	1	2
Incidence of malaria*, (95% CI)	0.03	0.04	0.06	0.02	0.03	0.08	0.01	0.02
	(0.02-0.06)	(0.02-0.09)	(0.02—0.16)	(0.00-0.11)	(0.01-0.08)	(0.03-0.23)	(0.00-0.08)	(0.00-0.1
lumber of routine visits, n	4,316	4,583	1164	1293	2034	1568	1118	1722
Prevalence of microscopic parasitemia***	2.9%	1.4%	1.8%	1.1%	4.4%	2.7%	1.3%	0.5% 7.7%
Prevalence of parasitemia by qPCR	14.4%	9.2%	5.8%	3.7%	17.0%	15.3%	18.5%	7.7%
Geometric mean parasite density****	3.41	3.06	4.86	13.06	6.31	4.20	1.09	1.02
Median complexity of infection, (IQR)	3 (1-7)	2 (1-2)	1 (1-2.5)	2 (1-2.3)	4 (2-9)	2 (1-2)	1 (1-2)	1 (1-2)
468 *per person-year 469 **Malaria includes 1 episode (1) 470 ***Parasitemia by light micros 471 ****Geometric mean parasite	copy includes	1 episode (fen	nale, 5-15 years	old) due to nor	•	oecies ( <i>P. oval</i>	e)	

<sup>468</sup> \*per person-year

<sup>\*\*</sup>Malaria includes 1 episode (female, < 5 years old), due to non-falciparum species (*P. malariae*) 469

<sup>\*\*\*</sup>Parasitemia by light microscopy includes 1 episode (female, 5-15 years old) due to non-falciparum species (*P. ovale*) 470

<sup>471</sup> \*\*\*\*Geometric mean parasite density in parasites/uL of all qPCR-positive routine visits

Table 2. Molecular force of infection (FOI) by clone and by infection event, stratified by age and sex

Molecular force of	Sex	Age category					
infection (FOI)		All	< 5 years	5-15 years	16 years or older		
By clone, ppy* (95% CI)	All	0.18 (0.13-0.24)	0.14 (0.07-0.28)	0.19 (0.08-0.43)	0.20 (0.08-0.46)		
	Male	0.19 (0.12-0.30)	0.16 (0.07-0.39)	0.19 (0.10-0.37)	0.22 (0.09-0.54)		
	Female	0.17 (0.09-0.31)	0.12 (0.03-0.49)	0.19 (0.08-0.45)	0.18 (0.06-0.54)		
By event, ppy* (95% CI)	All	0.14 (0.11-0.18)	0.09 (0.06-0.16)	0.16 (0.09-0.30)	0.16 (0.08-0.32)		
	Male	0.16 (0.11-0.22)	0.13 (0.07-0.27)	0.18 (0.11-0.28)	0.15 (0.07-0.29)		
	Female	0.13 (0.08-0.21)	0.06 (0.02-0.18)	0.14 (0.07-0.27)	0.17 (0.07-0.41)		

<sup>\*</sup>per person-year

Table 3. Hazard ratios for rates of clearance of infection, by clone and by infection event

Predictors	Catagorias	Hazard ratio by	clone (95% CI)	Hazard ratio by infection event (95% CI)		
	Categories	Unadjusted	Adjusted	Unadjusted	Adjusted	
Sex	Male	ref	ref	ref	ref	
	Female	1.92 (1.19-3.11)	1.82 (1.20 – 2.75)	2.30 (1.20 – 4.42)	2.07 (1.24 – 3.47)	
Age	16 years or greater	ref	ref	ref	ref	
	5-15 years	0.66 (0.39 – 1.10)	0.81 (0.49 – 1.36)	0.82 (0.39 – 1.74)	1.27 (0.72 – 2.25)	
	< 5 years	1.64 (0.79 – 3.41)	1.55 (0.76 – 3.17)	2.01 (0.80 – 5.00)	1.75 (0.87 – 3.53)	
Complexity of infection (COI)	Polyclonal (COI > 1)	ref		ref		
	Monoclonal (COI = 1)	1.63 (1.03 – 2.57)		0.95 (0.38 – 2.34)		
Infection status	Present at baseline	ref	ref	ref	ref	
	New infection	1.94 (1.22 – 3.07)	1.75 (1.05 – 2.94)	4.66 (2.58 – 8.42)	4.32 (2.59 – 7.20)	
Parasite density *		0.85 (0.69 – 1.06)	0.81 (0.65 – 1.00)	0.41 (0.32 – 0.51)	0.44 (0.35 - 0.54)	
de la companya de la	1 1 1 1 1 1 1					

<sup>\*</sup>Increasing parasite density (log10) in parasites/microliter, as measured by qPCR

REFERENCES

485

- 487 1. World malaria report 2019 [Internet]. [cited 2020 Aug 5]. Available from: https://www.who.int/publications-detail-redirect/9789241565721
- 489 2. Bousema T, Okell L, Felger I, Drakeley C. Asymptomatic malaria infections: detectability, 490 transmissibility and public health relevance. Nat Rev Microbiol. 2014;12(12):833–840. 491 PMID: 25329408
- 492 3. Okell LC, Bousema T, Griffin JT, Ouédraogo AL, Ghani AC, Drakeley CJ. Factors determining 493 the occurrence of submicroscopic malaria infections and their relevance for control. 494 Nature Communications. 2012 Dec 4;3(1):1–9.
- 495 4. Tadesse FG, Slater HC, Chali W, Teelen K, Lanke K, Belachew M, Menberu T, Shumie G,
  496 Shitaye G, Okell LC, Graumans W, van Gemert G-J, Kedir S, Tesfaye A, Belachew F, Abebe
  497 W, Mamo H, Sauerwein R, Balcha T, Aseffa A, Yewhalaw D, Gadisa E, Drakeley C, Bousema
  498 T. The Relative Contribution of Symptomatic and Asymptomatic Plasmodium vivax and
  499 Plasmodium falciparum Infections to the Infectious Reservoir in a Low-Endemic Setting in
  500 Ethiopia. Clin Infect Dis. 2018 01;66(12):1883–1891. PMID: 29304258
- 501 5. Slater HC, Ross A, Felger I, Hofmann NE, Robinson L, Cook J, Gonçalves BP, Björkman A, 502 Ouedraogo AL, Morris U, Msellem M, Koepfli C, Mueller I, Tadesse F, Gadisa E, Das S, 503 Domingo G, Kapulu M, Midega J, Owusu-Agyei S, Nabet C, Piarroux R, Doumbo O, Doumbo 504 SN, Koram K, Lucchi N, Udhayakumar V, Mosha J, Tiono A, Chandramohan D, Gosling R, 505 Mwingira F, Sauerwein R, Riley EM, White NJ, Nosten F, Imwong M, Bousema T, Drakeley 506 C. Okell LC. The temporal dynamics and infectiousness of subpatent Plasmodium 507 falciparum infections in relation to parasite density. Nature Communications. 2019 Mar 508 29;10(1):1433.
- 509 6. Zuk M, McKean KA. Sex differences in parasite infections: Patterns and processes. 510 International Journal for Parasitology. 1996 Oct 1;26(10):1009–1024.
- 7. Klein SL. Hormonal and immunological mechanisms mediating sex differences in parasite infection. Parasite Immunology. 2004;26(6–7):247–264.
- 8. Roberts CW, Walker W, Alexander J. Sex-Associated Hormones and Immunity to Protozoan Parasites. Clin Microbiol Rev. 2001 Jul 1;14(3):476–488.
- Desai M, Kuile FO ter, Nosten F, McGready R, Asamoa K, Brabin B, Newman RD.
   Epidemiology and burden of malaria in pregnancy. The Lancet Infectious Diseases. 2007
   Feb 1;7(2):93–104. PMID: 17251080
- Molineaux L, Gramiccia G, Organization WH. The Garki project<sup>®</sup>: research on the
   epidemiology and control of malaria in the Sudan savanna of West Africa [Internet]. World

Health Organization: 1980 [cited 2020 Feb 18]. Available from: 520 521 https://apps.who.int/iris/handle/10665/40316 522 11. Pathak S, Rege M, Gogtay NJ, Aigal U, Sharma SK, Valecha N, Bhanot G, Kshirsagar NA, 523 Sharma S. Age-Dependent Sex Bias in Clinical Malarial Disease in Hypoendemic Regions. 524 PLoS One [Internet]. 2012 Apr 25 [cited 2020 Feb 18];7(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338423/ PMCID: PMC3338423 525 526 12. Landgraf B, Kollaritsch H, Wiedermann G, Wernsdorfer WH. Parasite density of 527 Plasmodium falciparum malaria in Ghanaian schoolchildren: evidence for influence of sex 528 hormones? Transactions of the Royal Society of Tropical Medicine and Hygiene. 1994 529 Jan;88(1):73-74. 530 13. Camargo LMA, Colletto GMDD, Ferreira MU, Gurgel SDM, Escobar AL, Marques A, Krieger 531 H. Camargo EP. Silva LHPD. Hypoendemic Malaria in Rondonia (Brazil, Western Amazon 532 Region): Seasonal Variation and Risk Groups in an Urban Locality. The American Journal of 533 Tropical Medicine and Hygiene. 1996 Jul 1;55(1):32–38. 534 14. Abdalla SI, Malik EM, Ali KM. The burden of malaria in Sudan: incidence, mortality and disability – adjusted life – years. Malar J. 2007 Jul 28;6:97. PMCID: PMC1995207 535 536 15. Houngbedji CA, N'Dri PB, Hürlimann E, Yapi RB, Silué KD, Soro G, Koudou BG, Acka CA, Assi 537 S-B, Vounatsou P, N'Goran EK, Fantodji A, Utzinger J, Raso G. Disparities of Plasmodium 538 falciparum infection, malaria-related morbidity and access to malaria prevention and 539 treatment among school-aged children: a national cross-sectional survey in Côte d'Ivoire. 540 Malar J [Internet]. 2015 Jan 5 [cited 2020 Aug 5];14. Available from: 541 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326184/ PMCID: PMC4326184 542 16. Mulu A, Legesse M, Erko B, Belyhun Y, Nugussie D, Shimelis T, Kassu A, Elias D, Moges B. 543 Epidemiological and clinical correlates of malaria-helminth co-infections in southern 544 Ethiopia. Malar J. 2013 Jul 3;12:227. PMCID: PMC3706225 545 17. Moon JJ, Cho S-Y. Incidence patterns of vivax malaria in civilians residing in a high-risk 546 county of Kyonggi-do (Province), Republic of Korea. Korean J Parasitol. 2001 547 Dec;39(4):293-299. PMCID: PMC2721214 548 Finda MF, Moshi IR, Monroe A, Limwagu AJ, Nyoni AP, Swai JK, Ngowo HS, Minja EG, Toe 549 LP, Kaindoa EW, Coetzee M, Manderson L, Okumu FO. Linking human behaviours and 550 malaria vector biting risk in south-eastern Tanzania. PLoS One [Internet]. 2019 Jun 3 [cited 551 2020 Apr 8]; 14(6). Available from: 552 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546273/ PMCID: PMC6546273 19. Nhamoyebonde S, Leslie A. Biological Differences Between the Sexes and Susceptibility to 553

Tuberculosis. J Infect Dis. 2014 Jul 15;209(suppl\_3):S100–S106.

- 555 20. Bernin H, Lotter H. Sex Bias in the Outcome of Human Tropical Infectious Diseases:
- Influence of Steroid Hormones. J Infect Dis. 2014 Jul 15;209(suppl 3):S107–S113.
- 557 21. Fischer J, Jung N, Robinson N, Lehmann C. Sex differences in immune responses to infectious diseases. Infection. 2015 Aug 1;43(4):399–403.
- 559 22. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat 560 Rev Immunol. 2008 Sep;8(9):737–744.
- 561 23. Klein SL, Shann F, Moss WJ, Benn CS, Aaby P. RTS, S Malaria Vaccine and Increased
- Mortality in Girls. mBio [Internet]. 2016 Apr 26 [cited 2020 Feb 18];7(2). Available from:
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850267/PMCID: PMC4850267
- 564 24. Delić D, Ellinger-Ziegelbauer H, Vohr HW, Dkhil M, Al-Quraishy S, Wunderlich F.
- Testosterone response of hepatic gene expression in female mice having acquired
- testosterone-unresponsive immunity to Plasmodium chabaudi malaria. Steroids. 2011
- 567 Oct;76(10–11):1204–1212. PMID: 21669218
- 568 25. Wunderlich, F, Marinovski P, Peter W, Benten M, Schmitt-Wrede, H-P, Mossman H.
- Testosterone and Other Gonadal Factor(s) Restrict the Efficacy of Genes Controlling
- Resistance to Plasmodium Chabaudi Malaria [Internet]. Parasite immunology. 1991.
- 571 Parasite Immunology, 13: 357-367. doi:10.1111/j.1365-3024.1991.tb00289.x
- 572 26. Felger I, Maire M, Bretscher MT, Falk N, Tiaden A, Sama W, Beck H-P, Owusu-Agyei S,
- 573 Smith TA. The Dynamics of Natural Plasmodium falciparum Infections. PLOS ONE. 2012
- 574 Sep 18;7(9):e45542.
- 575 27. Smith T, Felger I, Fraser-Hurt N, Beck H-P. 10. Effect of insecticide-treated bed nets on the
- dynamics of multiple Plasmodium falciparum infections. Transactions of the Royal Society
- of Tropical Medicine and Hygiene. 1999 Feb 1;93:53–57.
- 578 28. Nankabirwa JI, Briggs J, Rek J, Arinaitwe E, Nayebare P, Katrak S, Staedke SG, Rosenthal PJ,
- Rodriguez-Barraguer I, Kamya MR, Dorsey G, Greenhouse B. Persistent Parasitemia
- Despite Dramatic Reduction in Malaria Incidence After 3 Rounds of Indoor Residual
- 581 Spraying in Tororo, Uganda, J Infect Dis. 2019 Mar 15;219(7):1104–1111. PMCID:
- 582 PMC6420168
- 583 29. Nankabirwa Jl, Arinaitwe E, Rek J, Kilama M, Kizza T, Staedke SG, Rosenthal PJ, Rodriguez-
- Barraguer I, Briggs J, Greenhouse B, Bousema T, Drakeley C, Roos DS, Tomko SS, Smith DL,
- Kamya MR, Dorsey G. Malaria Transmission, Infection, and Disease following Sustained
- Indoor Residual Spraying of Insecticide in Tororo, Uganda. The American Journal of
- Tropical Medicine and Hygiene; 2020 Jul 20;tpmd200250.
- 30. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive
- detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets.
- 590 PLoS Med. 2015 Mar;12(3):e1001788. PMCID: PMC4348198

- 591 31. Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, Thaithong S, Brown
- KN. High sensitivity of detection of human malaria parasites by the use of nested
- 593 polymerase chain reaction. Mol Biochem Parasitol. 1993 Oct;61(2):315–320. PMID:
- 594 8264734
- 595 32. Miller RH, Hathaway NJ, Kharabora O, Mwandagalirwa K, Tshefu A, Meshnick SR, Taylor
- 596 SM, Juliano JJ, Stewart VA, Bailey JA. A deep sequencing approach to estimate Plasmodium
- falciparum complexity of infection (COI) and explore apical membrane antigen 1 diversity.
- 598 Malar J. 2017 Dec 16;16(1):490. PMCID: PMC5732508
- 33. Hathaway NJ, Parobek CM, Juliano JJ, Bailey JA. SeekDeep: single-base resolution de novo clustering for amplicon deep sequencing. Nucleic Acids Res. 2018 Feb 28;46(4):e21–e21.
- 601 34. Lerch A, Koepfli C, Hofmann NE, Kattenberg JH, Rosanas-Urgell A, Betuela I, Mueller I,
- Felger I. Longitudinal tracking and quantification of individual Plasmodium falciparum
- clones in complex infections. Sci Rep [Internet]. 2019 Mar 4 [cited 2020 Feb 18];9.
- Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399284/ PMCID:
- 605 PMC6399284
- 35. Koepfli C, Mueller I. Malaria Epidemiology at the Clone Level. Trends Parasitol. 2017 Dec;33(12):974–985. PMCID: PMC5777529
- 608 36. Nguyen T-N, von Seidlein L, Nguyen T-V, Truong P-N, Hung SD, Pham H-T, Nguyen T-U, Le
- TD, Dao VH, Mukaka M, Day NP, White NJ, Dondorp AM, Thwaites GE, Hien TT. The
- persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium
- 611 vivax infections over time in Vietnam: an open cohort study. Lancet Infect Dis. 2018
- 612 May; 18(5):565–572. PMCID: PMC5910058
- 613 37. Koepfli C, Schoepflin S, Bretscher M, Lin E, Kiniboro B, Zimmerman PA, Siba P, Smith TA,
- Mueller I, Felger I. How much remains undetected? Probability of molecular detection of
- 615 human Plasmodia in the field. PLoS ONE. 2011 Apr 28;6(4):e19010. PMCID: PMC3084249
- 38. Ross A, Koepfli C, Li X, Schoepflin S, Siba P, Mueller I, Felger I, Smith T. Estimating the
- 617 numbers of malaria infections in blood samples using high-resolution genotyping data.
- 618 PLoS ONE. 2012;7(8):e42496. PMCID: PMC3430681
- 39. Lerch A, Koepfli C, Hofmann NE, Messerli C, Wilcox S, Kattenberg JH, Betuela I, O'Connor L,
- Mueller I, Felger I. Development of amplicon deep sequencing markers and data analysis
- 621 pipeline for genotyping multi-clonal malaria infections. BMC Genomics. 2017 Nov
- 622 13;18(1):864.
- 623 40. R Core Team. R: A language and environment for statistical computing. [Internet]. R
- Foundation for Statistical Computing, Vienna, Austria.; 2019. Available from: URL
- https://www.R-project.org/.

41. Python Language Reference, version 3.7.4. [Internet]. Python Software Foundation.; 626 627 Available from: Available at http://www.python.org 628 42. Rondeau V, Gonzalez JR. frailtypack: A computer program for the analysis of correlated failure time data using penalized likelihood estimation. Computer Methods and Programs 629 630 in Biomedicine. 2005 Nov 1;80(2):154-164. 631 43. Rondeau V, Marzroui Y, Gonzalez JR. frailtypack: An R Package for the Analysis of 632 Correlated Survival Data with Frailty Models Using Penalized Likelihood Estimation or 633 Parametrical Estimation. Journal of Statistical Software. 2012 Apr 17;47(1):1–28. 634 44. Briggs J. 2020. Sex based differences. Github. 635 https://github.com/EPPIcenter/sex based differences.git. cf6c325.